|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
CZ294251B6
(cs)
*
|
2000-06-27 |
2004-11-10 |
Laboratorios S. A. L. V. A. T., S. A. |
Karbamáty a jejich použití pro výrobu farmaceutického prostředku
|
|
JP4445704B2
(ja)
|
2000-12-22 |
2010-04-07 |
アルミラル・ソシエダッド・アノニマ |
キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
|
|
IL156558A0
(en)
|
2000-12-28 |
2004-01-04 |
Almirall Prodesfarma Ag |
Novel quinuclidine derivatives and medicinal compositions containing the same
|
|
EP1463481A4
(en)
|
2001-12-14 |
2008-06-25 |
Targacept Inc |
METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
|
|
EP1461336B1
(en)
*
|
2001-12-20 |
2013-05-22 |
CHIESI FARMACEUTICI S.p.A. |
1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
|
|
ES2203327B1
(es)
*
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
ES2204295B1
(es)
*
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
|
AU2002345266B2
(en)
|
2002-07-08 |
2009-07-02 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
|
TW200800953A
(en)
|
2002-10-30 |
2008-01-01 |
Theravance Inc |
Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
|
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
|
WO2004089898A1
(en)
|
2003-04-09 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
EA009387B1
(ru)
|
2003-04-11 |
2007-12-28 |
Рэнбакси Лабораториз Лимитед |
Азабициклические производные в качестве антагонистов мускаринового рецептора
|
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
|
DE602004021921D1
(de)
|
2003-05-28 |
2009-08-20 |
Theravance Inc |
Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
|
|
WO2005007645A1
(en)
|
2003-07-11 |
2005-01-27 |
Theravance, Inc. |
Substituted 4-amino-1-benzylpiperidine compounds
|
|
US7345060B2
(en)
|
2003-11-21 |
2008-03-18 |
Theravance, Inc. |
Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
TW200538095A
(en)
|
2004-03-11 |
2005-12-01 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TWI341836B
(en)
|
2004-03-11 |
2011-05-11 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
JP2007528412A
(ja)
|
2004-03-11 |
2007-10-11 |
セラヴァンス， インコーポレーテッド |
ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
|
|
JP2007528413A
(ja)
|
2004-03-11 |
2007-10-11 |
セラヴァンス， インコーポレーテッド |
ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
|
|
EP1723109A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
EP1723115A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
WO2005087735A1
(en)
|
2004-03-11 |
2005-09-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7262205B2
(en)
|
2004-03-11 |
2007-08-28 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
ES2246170B1
(es)
*
|
2004-07-29 |
2007-04-01 |
Almirall Prodesfarma, S.A. |
Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
EP1856112A1
(en)
|
2005-03-10 |
2007-11-21 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
EP1856049A1
(en)
|
2005-03-10 |
2007-11-21 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TW200714587A
(en)
|
2005-03-10 |
2007-04-16 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
WO2006099167A1
(en)
|
2005-03-10 |
2006-09-21 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7659403B2
(en)
|
2005-03-10 |
2010-02-09 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
WO2006138218A1
(en)
|
2005-06-13 |
2006-12-28 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
BRPI0614874A2
(pt)
|
2005-08-22 |
2011-04-19 |
Targacept Inc |
diazatricicloalcanos substituìdos com heteroarila, métodos para sua preparação e uso dos mesmos
|
|
RU2421464C2
(ru)
|
2005-10-21 |
2011-06-20 |
Новартис Аг |
Человеческие антитела к il-13 и их терапевтическое применение
|
|
WO2007110782A1
(en)
*
|
2005-12-30 |
2007-10-04 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
GB0602778D0
(en)
|
2006-02-10 |
2006-03-22 |
Glaxo Group Ltd |
Novel compound
|
|
EP2322525B1
(en)
|
2006-04-21 |
2013-09-18 |
Novartis AG |
Purine derivatives for use as adenosin A2A receptor agonists
|
|
ES2298049B1
(es)
|
2006-07-21 |
2009-10-20 |
Laboratorios Almirall S.A. |
Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
|
|
EP1882691A1
(en)
*
|
2006-07-26 |
2008-01-30 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine derivatives as M3 antagonists
|
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
|
TW200825084A
(en)
*
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
PL2104535T3
(pl)
|
2007-01-10 |
2011-05-31 |
Irm Llc |
Związki i kompozycje jako inhibitory proteazy aktywujące kanały
|
|
KR20090107567A
(ko)
*
|
2007-02-09 |
2009-10-13 |
아스텔라스세이야쿠 가부시키가이샤 |
아자 가교환 화합물
|
|
US20090010923A1
(en)
*
|
2007-04-24 |
2009-01-08 |
University Of Maryland, Baltimore |
Treatment of cancer with anti-muscarinic receptor agents
|
|
DE602008005140D1
(de)
|
2007-05-07 |
2011-04-07 |
Novartis Ag |
Organische verbindungen
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
DK2217597T3
(da)
|
2007-10-01 |
2011-06-20 |
Comentis Inc |
Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
|
|
EP2065385A1
(en)
*
|
2007-11-28 |
2009-06-03 |
Laboratorios SALVAT, S.A. |
Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
|
|
MX2010006421A
(es)
|
2007-12-10 |
2010-06-25 |
Novartis Ag |
Compuestos organicos.
|
|
MX2010007604A
(es)
|
2008-01-11 |
2010-08-02 |
Novartis Ag |
Pirimidinas como inhibidores de cinasa.
|
|
EP2080507A1
(en)
*
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Pharmaceutical formulations comprising an anticholinergic drug
|
|
JP2011511845A
(ja)
|
2008-02-13 |
2011-04-14 |
ターガセプト，インコーポレイテッド |
アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
|
|
GB2468073B
(en)
|
2008-02-26 |
2012-09-05 |
Elevation Pharmaceuticals Inc |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
|
|
US20100055045A1
(en)
*
|
2008-02-26 |
2010-03-04 |
William Gerhart |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
JP2011522860A
(ja)
|
2008-06-10 |
2011-08-04 |
ノバルティス アーゲー |
上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
|
|
EP2154136A1
(en)
|
2008-08-08 |
2010-02-17 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine carbonate derivatives and medicinal compositions thereof
|
|
US20100112606A1
(en)
*
|
2008-10-17 |
2010-05-06 |
Michael Armstrong |
Measurement and analysis of leukotrienes
|
|
EP2206712A1
(en)
*
|
2008-12-23 |
2010-07-14 |
CHIESI FARMACEUTICI S.p.A. |
"Alkaloid aminoester derivatives and medicinal composition thereof"
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
JP5781510B2
(ja)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
|
|
PE20121148A1
(es)
|
2009-08-17 |
2012-09-07 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
|
JP5775871B2
(ja)
|
2009-08-20 |
2015-09-09 |
ノバルティス アーゲー |
ヘテロ環式オキシム化合物
|
|
MX2012004792A
(es)
|
2009-10-22 |
2013-02-01 |
Vertex Pharma |
Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
KR20130111967A
(ko)
|
2010-06-22 |
2013-10-11 |
키에시 파르마슈티시 엣스. 피. 에이. |
항무스카린성 약물을 포함하는 건조 분말 제제
|
|
KR20130111968A
(ko)
|
2010-06-22 |
2013-10-11 |
키에시 파르마슈티시 엣스. 피. 에이. |
알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
|
|
KR20130087406A
(ko)
|
2010-06-22 |
2013-08-06 |
키에시 파르마슈티시 엣스. 피. 에이. |
알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
|
|
KR20130087405A
(ko)
|
2010-06-22 |
2013-08-06 |
키에시 파르마슈티시 엣스. 피. 에이. |
알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
CA2820600A1
(en)
|
2010-11-26 |
2012-05-31 |
Chiesi Farmaceutici S.P.A. |
Glycine derivatives and their use as muscarinic receptor antagonists
|
|
KR101928505B1
(ko)
*
|
2011-01-28 |
2018-12-12 |
에스케이바이오팜 주식회사 |
피리돈 유도체 및 이를 포함하는 약학적 조성물
|
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
US20120220557A1
(en)
|
2011-02-17 |
2012-08-30 |
Chiesi Farmaceutici S.P.A. |
Liquid propellant-free formulation comprising an antimuscarinic drug
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
WO2012116217A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
AU2012231275A1
(en)
*
|
2011-03-18 |
2013-10-17 |
Genzyme Corporation |
Glucosylceramide synthase inhibitors
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
CA2834467A1
(en)
*
|
2011-04-29 |
2012-11-01 |
Chiesi Farmaceutici S.P.A. |
Alkaloid ester and carbamate derivatives and medicinal compositions thereof
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
EA026655B1
(ru)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
CA2856803A1
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
RU2628082C2
(ru)
|
2011-12-30 |
2017-08-14 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Хинуклидиновые эфиры 1-азагетероциклилуксусной кислоты в качестве антимускариновых средств, способ их получения и их лекарственные композиции
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
JP2015512425A
(ja)
|
2012-04-03 |
2015-04-27 |
ノバルティス アーゲー |
チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
|
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
EP3134397A1
(en)
|
2014-04-24 |
2017-03-01 |
Novartis AG |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
KR20160145780A
(ko)
|
2014-04-24 |
2016-12-20 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
|
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
|
US20170166561A1
(en)
|
2014-07-11 |
2017-06-15 |
Alpharmagen, Llc |
Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
ES2831416T3
(es)
|
2014-07-31 |
2021-06-08 |
Novartis Ag |
Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
|
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
|
CN114040762A
(zh)
|
2019-02-04 |
2022-02-11 |
建新公司 |
使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
|
|
WO2020250116A1
(en)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
|
PE20220346A1
(es)
|
2019-08-28 |
2022-03-14 |
Novartis Ag |
Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
|
|
TW202142236A
(zh)
|
2020-02-03 |
2021-11-16 |
美商健臻公司 |
用於治療與溶體儲積症相關的神經症狀之方法
|
|
KR20230043024A
(ko)
|
2020-07-24 |
2023-03-30 |
젠자임 코포레이션 |
벤글루스타트를 포함하는 제약 조성물
|